Items Tagged ‘major depressive disorder’
October 4, 2022
Mayo study lays foundation to predict antidepressant response in people with suicide attempts
By Susan Murphy 
Mayo Clinic researchers have discovered that people with major depressive disorder and a history of attempted suicide have distinct biomarkers that correlate with their response to antidepressant therapy. The new findings, published in Frontiers Pharmacology, are key to individualized treatment strategies and early identification of patients who are at the highest risk for suicide. For […]
Tags: center for individualized medicine, depression, genomics, major depressive disorder, personalized medicine
June 29, 2022
Mayo study validates threshold to determine when an antidepressant is ineffective
By Susan Murphy
Mayo Clinic researchers have validated a threshold designed to help determine if an antidepressant used for depression is working, but not well enough to be continued.
Tags: #Dr. William Bobo, antidepressants, center for individualized medicine, depression, genomics, individualized medicine, major depressive disorder, medical research, personalized medicine
February 8, 2021
Mayo Clinic algorithm shows potential in individualizing treatment for depression
By Susan Murphy
Finding an effective antidepressant medication for people diagnosed with depression, also called major depressive disorder, is often a long and complex process of “try and try again” ― going from one prescription to the next until achieving a therapeutic response. This complex disease, which affects more than 16 million people in the U.S., can cause […]
Tags: #algorithm, #Artificial Intelligence, depression, Genetics, major depressive disorder
July 15, 2014
Genome-Wide Associations of Citalopram and Escitalopram Plasma Drug and Metabolite Concentrations
By Center for Individualized Medicine 
Published in the British Journal of Clinical Pharmacology, a team of researchers from the Mayo Clinic, led by the director of the Center for Individualized Medicine’s Pharmacogenomics Program, Richard Weinshilboum, M.D., applied a genome-wide association study (GWAS) to identify genetic factors that contribute to variation in plasma concentrations of Citalopram (CT) or escitalopram (S-CT), and […]
Tags: center for individualized medicine, citalopram, DNA, DNA Sequencing, dna test, DNA Testing, escitalopram, gene sequencing, genetic, Genetics, genome, genome science
March 13, 2014
Citalopram and Escitalopram Plasma Drug and Metabolite Concentrations: Genome-Wide Associations
A recently published article in the area of Pharmacogenomics set out to identify genetic factors in Citalopram (CT) and escitalopram (S-CT), which are among the most widely prescribed serotonin reuptake inhibitors (SSRIs) used to treat Major Depressive Disorder (MDD), that contribute to variation in plasma concentrations of CT or S-CT and their metabolites in MDD patients treated […]
Tags: citalopram, dna test, DNA Testing, escitalopram, gene sequencing, genome science, genome-wide association studies, genomic medicine, genomics, individualized medicine, major depressive disorder, personal genomics